A recent study has raised alarm over websites selling compounded versions of popular weight-loss drugs, such as Novo Nordisks Wegovy and Eli Lillys Zepbound, often without disclosing crucial safety risks
Dysbiosis impairs incretin signaling, reducing the effectiveness of GLP-1 therapies
A 1mL (100 unit) insulin syringe works for most tirzepatide dosing ranges
Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms
Last reviewed: June 1, 2026 Last updated: June 1, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Useful for understanding where GLP-1 medications fit in the broader category of evidence-based weight management